I do want to have a open discussion on the "IMU internal conversation" given now the beautiful data from Her-vass validates entire b-cell platform including those combo, IDMC feedback, fundings and many many more to take in consideration.
Maybe
Reduce the patient numbers per IDMC to fast-track the trails
or
Keep the current study to play safe on FDA approval perspective
or
Sell it to bigpharm for funding and focus on the combination and CF33
or
.
.
.
What would you do if you are LC/PH?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $104.5M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.4¢ | 1.2¢ | $134.2K | 10.31M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 1168170 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 9464131 | 33 |
| Last trade - 16.10pm 01/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |
Day chart unavailable